Cabaletta Bio: Eight insiders buy shares of the biotech following the announcement of strategic priorities!

Cabaletta Bio (CABA) specializes in revolutionizing autoimmune treatment through cell therapy. The company is pursuing a potentially curative approach with its CARTA strategy (Chimeric Antigen Receptor T cells for Autoimmunity). The centerpiece of its portfolio is Rese-cel (formerly CABA-201), a CD19-CAR-T cell therapy. Through a single infusion of the patient's own genetically modified T cells, the disease-causing B cells in the body are profoundly and transiently eliminated. This allows the immune system to "reset," enabling healthy B cells to...